DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Reshma Kewalramani - 2 Kewalramani - 1 Jim Cramer - 1 painkiller - 1 Michael Yee - 1
Top related locs:
Boston U.S
Top related orgs:
Vertex Pharma - 1 Pharma - 1 Vertex Pharmaceuticals - 1 Food and Drug - 1 Wall Street - 1 CRISPR Therapeutics - 1 Jefferies - 1

Search resuls for: "Reshma Kewalramani"


5 mentions found


☆ Vertex Pharma CEO Kewalramani sits down with Jim Cramer
  + stars: | 2024-02-08 | by ( Jim Cramer | ) www.cnbc.com   time to read: 1 min
Vertex Pharma CEO Kewalramani sits down with Jim CramerVertex Pharma President and CEO Dr. Reshma Kewalramani joins 'Mad Money' host Jim Cramer to talk sickle cell gene therapy, cystic fibrosis treatments and more.
Persons: Kewalramani, Jim Cramer, Reshma Kewalramani Organizations: Vertex Pharma, Pharma
☆ Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
  + stars: | 2024-01-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Acute pain is usually caused by injury, surgery, illness, trauma or painful medical procedures and is likely to ease with time. Around 80 million patients are prescribed a medicine for their moderate-to-severe acute pain every year in the U.S., Vertex said in a release. Last year, the company's painkiller produced positive results in a mid-stage trial in diabetes patients suffering from a chronic nerve condition. Those two procedures are commonly used in studies of people with acute pain. Jefferies analyst Michael Yee said the drug's failure to meet that goal is in line with expectations and that overall, the late-stage trial results released Tuesday are positive.
Persons: Reshma Kewalramani, painkiller, Michael Yee Organizations: Vertex Pharmaceuticals, Food and Drug, Wall Street, CRISPR Therapeutics, Jefferies Locations: Boston, U.S
☆ A year after hitting a record, here are the biggest Nasdaq-100 winners and losers
  + stars: | 2022-11-20 | by ( Fred Imbert | ) www.cnbc.com   time to read: +3 min
On Nov. 19, 2021, the Nasdaq-100 index — which is made up of the 100-largest Nasdaq Composite stocks — hit a record closing high of 16,573.34. DocuSign and Zoom Video have fallen more than 80% and 67%, respectively, since the Nasdaq-100 reached its record high. Megacap stocks such as Meta Platforms , Tesla and Amazon have also plunged over the past 12 months, in part due to their high valuations. Vertex Pharmaceuticals has rallied 69.5% since the Nasdaq-100 closed at a record. O'Reilly Automotive, T-Mobile and Gilead Sciences are also among the big Nasdaq-100 winners over the year since the Nasdaq closed at an all-time high.
☆ Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn
  + stars: | 2022-10-12 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +8 min
CRISPR companies are faring better by producing faster and more dramatic clinical results. A layoff tracker from Fierce Biotech counts at least 90 drug companies that have laid off staff in 2022. Gene-editing biotechs have avoided the brunt of the downturn because of fast clinical successIntellia Therapeutics is developing CRISPR-based gene-editing medicines that could cure diseases. Just in the past month, CRISPR Therapeutics moved into a swanky new headquarters in Boston that can house up to 1,000 people. BeamTo be sure, 2022 hasn't been smooth sailing for the CRISPR companies.
☆ We went inside the lab at Vertex, a company that dodged the market downturn to become one of the best-performing biotechs of 2022
  + stars: | 2022-09-21 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +10 min
A mosaic of human cells inside Vertex Pharmaceuticals' cell and gene-therapy laboratory. The four-story, 267,000-square-foot space is home to Vertex's cell and gene-therapy unit, with about 375 people now residing in the modern-industrial building. That has led to going after unrelated diseases like sickle cell, diabetes, muscular dystrophy, kidney disease, and pain. For instance, Vertex's approach to sickle cell is led by its CRISPR gene-editing program. Vertex PharmaceuticalsThe next test of Vertex's strategy will be an experimental treatment called exa-cel, its CRISPR gene-editing program for sickle cell.
0 next >>
Total: 5